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Abstract:  A new compound maleimide-5-oxime was isolated, together with 3,4-
dihydroxybenzoic acid, tetillapyrone, from the ethyl acetate extract of the marine sponge 
Haliclona baeri while tetillapyrone, nortetillapyrone, p-hydroxybenzaldehyde and 
phenylacetic acid were isolated from the ethyl acetate extract of Haliclona cymaeformis, Mar. Drugs 2007, 5                                                  
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collected from the Gulf of Thailand. The structures of tetillapyrone and nortetillapyrone 
were re-examined using HMBC correlations. Maleimide-5-oxime, tetillapyrone and 
nortetillapyrone were found to be inactive against three human tumor cell lines (the 
estrogen-dependent ER(+) MCF-7, the estrogen-independent ER(-) MDA-MB-231 and 
NCI-H460. Maleimide-5-oxime, p-hydroxybenzaldehyde, phenylacetic acid, tetillapyrone 
and nortetillapyrone were evaluated for their growth inhibitory effect against seven yeasts 
and eight filamentous fungi. Only nortetillapyrone showed antifungal activity, with a 
preponderance on the dermatophytic filamentous fungi. 
Keywords:  Haliclona baeri, Haliclona cymaeformis, tetillapyrone, nortetillapyrone, 
antifungal activity, dermatophytes 
 
1. Introduction 
 
The frequency of invasive fungal infection has risen substantially with the increasing numbers of 
immunocompromised patients, such as those infected with HIV, receiving cancer chemotherapy, 
immunosuppressive therapy, or treatment with broad-spectrum antibiotics [1]. The most frequently 
encountered infections are caused by the yeast Candida albicans and by species of filamentous fungus 
Aspergillus. Other fungal pathogens that have emerged in recent years include yeast species such as 
Candida glabata, C. krusei, C. tropicalis, Cryptococcus and Trichosporon and filamentous fungi such 
as Fusarium, Rhizopus and Rhizomucor [2]. On the other hand, dermatophytes, which invade and 
multiply in keratinized tissues [3] and cause infection, have a worldwide distribution with 
geographical differences in the incidence and prevalence of different dermatophyte species [4] and the 
most common agents belong to three genera: Epidermophyton,  Trichophyton and Microsporum. 
Majority of clinically used antifungals suffer from various drawbacks in terms of toxicity, efficacy and 
cost, and their frequent use has led to the emergence of resistant strains. Hence, there is a great demand 
for novel antifungal agents belonging to the wide range of structural classes, selectively acting on 
novel targets with fewer side effects [5]. 
There is mounting evidence that fungi display highly specific adaptations in the marine 
environment that include the production of unique secondary metabolites antibiotics [1]. The fact that 
marine organisms contain secondary metabolites different from their terrestrial counterparts in 
structure and biological activity has led to the hypothesis that marine organisms may contain efficient 
antifungal compounds, with different modes of action and selective antifungal activity compared with 
human cells [6]. 
Sponges in the genus Haliclona are well-known for producing a variety of secondary metabolites, 
most commonly bioactive alkaloids [7] and many of which are cytotoxic [8]. Antifungal compounds 
isolated from Haliclona include haliclonadiamine, an alkaloid isolated from Haliclona sp. from Palau 
[9] and alkyl amino alcohols, halaminols A, B and C from the tropical marine sponge Haliclona sp., 
collected on the Great Barrier Reef [10].  Mar. Drugs 2007, 5                                                  
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In the course of our investigation on bioactive compounds from the marine sponges from the Gulf 
of Thailand, we have investigated the chemical constituents of the two marine sponges Haliclona baeri 
and Haliclona cymaeformis, collected from the coastal area of Chonburi Province and from Koh 
Chang, Trad Province, Eastern Thailand, respectively. Isolated from Haliclona baeri were a new 
maleimide-5-oxime (1), 3,4-dihydroxybenzoic acid (2), tetillapyrone (5  and 6 ) while Haliclona 
cymaeformis furnished, besides tetillapyrone (5 and 6), p-hydroxybenzaldehyde (3), phenylacetic acid 
(4) and nortetillapyrone (7 and 8) (Figure 1). We have also re-examined the structures of tetillapyrone 
and nortetillapyrone, previously reported by our group from Tetilla japonica [11], as well as 
investigated the antifungal activity of the isolated compounds.  
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Figure 1. Compounds isolated from Haliclona baeri and H. cymaeformis  
 
2. Results and Discussion 
 
We have previously reported isolation of tetillapyrone (5) and nortetillapyrone (8) from the marine 
sponge  Tetilla japonica, collected from the Gulf of Thailand [11].  Though the structures of both 
compounds were established by 
1H, 
13CNMR, COSY, NOESY, HETCOR, HMBC and HRMS as well 
as by X-ray analysis in the case of tetillapyrone (5), there were still some uncertainties with respect to Mar. Drugs 2007, 5                                                  
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the pyrone moiety. The correlations observed in the HMBC spectrum for both compounds raised some 
doubts about the correct position of the hydroxyl and carbonyl groups of the pyrone ring. In addition, 
the data obtained from the X-ray analysis did not provide any evidence if a hydrogen atom was 
attached to the oxygen atom on C-2 or on C-6. Besides, the positions of the hydroxyl and carbonyl 
groups of the pyrone ring in the structure of nortetillapyrone (8) were opposite to those observed in the 
pryrone ring of tetillapyrone (5). All of these evidences, combined with the new isolation of more 
quantities of tetillapyrone and nortetillapyrone from the marine sponges H. cymaeformis and H. baeri, 
have led us to re-examine their structures by careful analysis of the HMBC spectra of both compounds. 
The structure of tetillapyrone (5), previously proposed by us [11], was based on the fact that one 
carbon signal was missing in the 
13C NMR spectrum and thus the carbon signal at δ109.45 was 
attributed to C-3 and C-5 of the pyrone ring. As the protons of the methyl group (δ1.76s) on C-3 of the 
pyrone ring and the hydroxyl proton at δ11.28s, showed crosspeaks with the carbon at δ109.45, we 
have concluded that the hydroxyl group was on C-6. In fact, it is improbable that C-3 and C-5 could 
have the same chemical shift value as both carbons have completely different environment. Carefully 
examining the HMBC at 500 MHz spectrum of tetillapyrone (Table1), we have found that the methyl 
protons (δ1.78s) gave strong correlations to, besides C-4 (δ136.21), the carbons at δ109.43 (C-3), 150 
54 (C-6) and 163.85 (C-2). This was very strange since the methyl protons were five bonds away from 
C-5. On the other hand, the hydroxyl proton at δ11.30 brs (OH-6) showed also correlation with the 
carbon at δ109.43 (C-3), which is also of five bonds distance. However, the only chance for this to 
happen is that tetillapyrone does not exist as only one compound (5) but instead as two compounds (5 
and 6). Thus the correlations observed in the HMBC spectrum were due to the methyl protons (δ1.78s) 
with the carbons at δ150.54 (C-2 of compound 6) and δ163.85 (C-2 of compound 5), respectively. This 
also explains the correlation observed between the hydroxyl proton at δ11.30 brs (OH-2) and the 
carbon at δ109.43 (C-3) of compound 6. 
It is interesting to note that in the structure previously proposed for nortetillapyrone (8), the 
positions of the hydroxyl and carbonyl groups of the pyrone moiety were opposite to those found in 
the structure 5 of tetillapyrone. Though, the HMBC spectrum showed strong correlation between H-3 
(δ5.62) and the carbon at δ163.18, like that in structure 5 of tetillapyrone, the correlation between H-3 
and the hydroxyl proton at δ 11.23 brs observed in the COSY spectrum, has led to the conclusion that 
nortetillapyrone should have the structure 8. In this structure, the chemical shift values of the carbonyl 
carbon (δ150.48) and the enolic carbon (δ163.18) were opposite to those found in tetillapyrone (5). 
However, there is no satisfactory explanation for this incongruence. The only possibility is, like in the 
case of tetillapyrone, nortetillapyrone also exists, in solution, as two compounds (7 and 8). In this 
circumstance, the correlation observed in HMBC spectrum (Table 2) between H-4 (δ 5.52d) and the 
carbon at δ163.18 (C-2) was due to structure 7, while the correlation between H-4 (δ 5.52d) and the 
hydroxyl group at δ11.23 brs (OH-2), observed in the COSY spectrum, was due to structure 8. 
Since structures 5 and 6 of tetillapyrone are tautomers, they can exist in equilibrium in the solution. 
In the same way, structures 7 and 8 are also tautomers of nortetllapyrone and thus can also exist in 
equilibrium in the solution (Figure 2). 
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Table 1. 
1H and 
13C NMR data (500 MHz, DMSO) of tetillapyrone (5 and 6). 
______________________________________________________________________ 
Position  δH (Hz)
a   δC mult
b   COSY   HMBC 
______________________________________________________________________ 
2   -----    150.54/163.85      
3   -----    109.43 
4   7.72d  (1.0)   136.21    Me   Me,  C-2/C-6,   
          C - 3  
5   -----    ? 
6   -----    150.54/163.85 
7   6.18t  (6.4)   83.75    H-8   C-4,  C-6 
8   2.08m    39.49    H-7,  H-9  C-7,  C-9 
9   4.25q  (3.1)   70.45    H-8,  H-10 
10    3.77dd (6.7, 3.8)  87.30      H-9, H-11  C-9, C-7 
11   3.60dd  (11.8,  3.8)  61.35    H-10    
  3.55dd  (11.8,  3.8)       C-9 
CH3   1.78d  (1.0)   12.36    H-4   C-3,  C-4,   
          C - 2 / C - 6  
OH-2   11.30  brs   -----      C-3 
OH-9   5.27d  (4.1)   -----      C-8,  C-9,   
          C - 1 0  
OH-11   5.06t  (5.1)   -----      C-10,  C-11 
______________________________________________________________________ 
a J values in parenthesis. 
bMultiplicities deduced by DEPT. 
Table 2. 
1H and 
13C NMR data (500 MHz, DMSO) of nortetillapyrone (7 and 8) 
______________________________________________________________________ 
Position  δH (Hz)
a   δC mult
b   COSY   HMBC 
______________________________________________________________________ 
2   -----    150.48/163.18     
3   6.52d  (8.1)   101.78    H-4   C-4,  C-2  (w) 
4   7.85d  (8.1)   140.56    H-3   C-7(w),  C-3,   
          C - 2 / C - 6  
5   -----    ?        
6      150.48/163.18 
7   6.13t  (7.0)   84.11    H-8   C-4,  C-2/C-6 
8   2.10m    39.75    H-7,  H-9  C-7,  C-9 
9   4.21m    70.40    H-8,  H-10 
10   3.76dd  (6.4,  3.2)  87.43    H-9,  H-11  C-11 
11   3.53m    61.27    H-10 
OH-2   11.23brs   ----- 
OH-9   8.45brs  ----- 
OH-11   ----    ----- 
______________________________________________________________________ 
a J values in parenthesis. 
bMultiplicities deduced by DEPT ;  w = weak 
 Mar. Drugs 2007, 5                                                  
 
45
O
O O O
CH3
H
H
H
H
H
H
O H
H
H
O
O OH O
CH3
H
H
H
H
H
H
O H
H
O
O O O
H
H
H
H
H
H
H
O H
H
H
O
O OH O
H
H
H
H
H
H
H
O H
H
11
5
11
6
11
7
11
8  
 
Figure 2. Tautomerization of tetillapyrone (5, 6) and nortetillapyrone (6, 7). 
 
The structure of compound 1 was identified as maleimide-5-oxime by spectroscopic and HRMS 
data. EIHRMS of compound 1 gave the molecular ion peak at 122.02723, indicating its molecular 
formula as C4H4N2O2 (cald.122.02728). The 
1H and 
13C NMR spectra of compound 1 were very 
simple, showing the proton and chemical shift values very similar to those observed for 3-
methylmaleimide-5-oxime, previously isolated from the marine sponge Pseudoceratina purpurea by 
our group [12]. However, the 
1HNMR of compound 1 showed two doublets of two coupled protons at 
δ 7.40d (J=7.6 Hz) and 5.45d (J=7.6 Hz) instead of the signals of the vinylic methyl protons (δ 1.73d, 
J=0.9Hz) and a vinylic proton (δ 7.2.6d, J=0.9Hz).  
In order to investigate the biological activity of the constituents of the two marine sponges, 
maleimide-5-oxime (1), p-hydroxybenzaldehyde (3), phenylacetic acid (4), tetillapyrone (5 and 6), and 
nortetillapyrone (7 and 8) were evaluated for their growth inhibitory effect against seven yeasts 
(Candida albicans, C. glabata, C. dubliniensis, C. tropicalis, C. krusei, C. parapsilosis, Cryptococcus 
neoformans), three non dermatophyte filamentous fungi (Aspergillus fumigatus, A. flavus, A. niger) 
and five dermatophyte filamentous fungi (Microsporum gypseum,  M. canis,  Trichophyton 
mentagrophytes,  T. rubrum and Epidermophyton floccosum). Maleimide-5-oxime (1),  p-
hydroxybenzaldehyde (3), phenylacetic acid (4) and tetillapyrone (5 and 6) were found to be inactive 
against all the test organisms (MIC > 250 μg/mL). Among the compounds tested, only nortetillapyrone 
(7, 8) showed growth inhibitory effect against tested fungal strains. Interestingly, some selectivity was 
observed for this compound. It showed no activity against Candida albicans, C. krusei and C. 
parapsilosis even at maximum concentration tested (250 μg/mL). However, nortetillapyrone showed 
some activity against C. tropicalis (250 μg/mL) and good activity against C. glabrata (62.5-31.25 Mar. Drugs 2007, 5                                                  
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μg/mL), C. dubliniensis (62.5 μg/mL) and Cryptococcus neoformans (31.25 μg/mL). In Addition, this 
compound exhibited significant antifungal activity against dermatophytes with the MIC values ranging 
from 31.25 to 125 μg/mL. It was more active against Microsporum canis (31.25 μg/mL) and less 
active against Trichophyton rubrum (62.5-125 μg/mL). Nortetillapyrone showed no activity against 
Aspergillus species even at maximum concentration tested (250 μg/mL). 
 
Table 3. Antifungal activity (MIC) of nortetillapyrone (7, 8) for Candida, Aspergillus and 
dermatophyte strains. 
 
________________________________________________________________________ 
      M I C   ( μg/ml) 
________________________________________________________________________ 
Test strain    nortetillapyrone (7, 8)    Fuconazole  Amphotericin  B 
________________________________________________________________________ 
 
Yeasts 
Candida albicans      >250    1   NT 
C.  glabata     31.25-62.5   32   NT 
C. dubliniensis      62.5    NT   NT 
C.  tropicalis     250    4   NT 
C.  krusei     >250    64-128   NT 
C. parapsilosis      >250    <1   NT 
Cryptococcus neoformans    31.25    NT   NT 
 
Filamentous fungi, Aspergillus 
Aspergillus fumigatus     >250    NT   1 
A.  flavus     >250    NT   1-2 
A.  niger     >250    NT   2 
 
Filamentous fungi, dermatophytes 
Microsporum gypseum    62.5    >128   NT 
M.  canis     31.25    128   NT 
Trichophyton mentagrophytes  125    16-32   NT 
T.  rubrum     62.5-125   16-32   NT 
Epidermophyton floccosum    62.5    16   NT 
_______________________________________________________________________ 
NT = not tested 
 
Maleimide-5-oxime (1), tetillapyrone (5 and 6), and nortetillapyrone (7 and 8) were also evaluated 
for their capacity to inhibit the in vitro growth of three human tumor cell lines, namely the estrogen-
dependent ER(+) MCF-7 (human breast adenocarcinoma), the estrogen-independent ER(-) MDA-MB-
231 (human breast adenocarcinoma) and NCI-H460 (non-small cell lung cancer). Maleimide-5-oxime 
(1) and tetillapyrone (5 and 6) were found to be inactive against all the cell lines tested (GI50 > 200 
μM) while nortetillapyrone (7 and 8) only weakly inhibited the growth of estrogen-independent ER (-) Mar. Drugs 2007, 5                                                  
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MDA-MB-231 cell line (GI50 = 155.7 μM) but was inactive against the estrogen-dependent ER (+) 
MCF-7 and NCI-H460 cell lines (GI50 > 200 μM). 
 
3. Conclusion 
 
As most antifungal compounds from marine origin are cytotoxic, consequently they have not 
generally been considered promising antifungal agents for clinical application [6].  Though many 
secondary metabolites from marine source were reported for their antifungal activity, their cytotoxic 
effect has not been measured. From this point of view, nortetillapyrone showed a very interesting 
biological activity profile. This compound not only selectively inhibits the growth of dermatophytes 
but also possesses no cytotoxicity against the tumor cell lines. Consequently, the structural feature of 
nortetillapyrone could serve as a model for development of a potential antifungal agent with 
therapeutic value. 
 
4. Experimental 
 
4.1. General 
1H and 
13C NMR spectra were recorded at ambient temperature in CDCl3 and DMSO on a Bruker 
AMC instrument operating at 300.12 and 75.47 MHz, respectively or a Bruker DRX instrument 
operating at 500, respectively 125 MHz. EI mass spectra were measured on a Hitachi Perkin-Elmer 
RMV-6M instrument. HRMS spectra were measured on a Kratos concept II 2 sector mass 
spectrometer. The accelerating voltage was 8 kV. Si gel for chromatography was silica gel 60 (0.2-0.5 
mm Merck) for analytical work and for preparative work TLC silica gel 60 GF 254 Merck. 
 
4.2. Animal material 
Haliclona cymaeformis (Esper, 1794) order Haplosclerida, family Chalinidae,  was collected by 
Scuba diving in the Gulf of Thailand near Koh Chang (2 meter depth), Trad Province in March 2004. 
Haliclona baeri (Wilson, 1952) was also collected by Scuba diving in the in the coastal area of 
Chonburi Province (3 meter depth). The sponge materials were identified by Dr. Sumaitt Putchakarn 
and the vouchers of the specimens, registered as BIMS-I 953 and BIMS-I 1766, respectively were 
deposited at Bangsaen Institute of Marine Science (BIMS), Burapha University, Bangsaen, Chonburi, 
Thailand. The materials were frozen immediately at -20ºC prior to extraction. 
 
4.3. Extraction, isolation and characterization of the constituents of Haliclona baeri 
The sample (1.3 kg net weight) was thawed, homogenized with EtOH (3 L), allowed to stand for 24 
h in a dark chamber and filtered. The residue on the filter paper was again extracted with EtOH 
(2x3L), the aqueous alcoholic extracts were combined, evaporated at reduced pressure to ca. 500 ml 
and extracted with EtOAc (3x500mL). The EtOAc extracts were combined and concentrated at 
reduced pressure to give the crude EtOAc extract. This (10 g) was chromatographed over a Si gel 
column (120g) and eluted with petrol-CHCl3 and CHCl3-Me2O, 350 ml fractions being eluted as Mar. Drugs 2007, 5                                                  
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follows. Frs 1-62 (petrol-CHCl3, 1:1), 63-78 (petrol-CHCl3, 3:7), 79-95 (petrol-CHCl3, 1:9), 96-182 
(CHCl3-Me2O, 4:1), 183-206 (CHCl3- Me2O, 3:2). Frs 101-114 were combined (107.8 mg) and 
purified by TLC (Si gel, CHCl3-Me2O–HCO2H, 5:5:0.1) to give 8.6 mg of maleimide 5-oxime (1). Frs 
125-198 were combined (185.6 mg) and purified by TLC (Si gel, CHCl3-MeOH-HCO2H, 93:7:1) to 
give 13.1 mg 3,4-dihydroxybenzoic acid (2) and 8.0 mg of tetillapyrone (5and 6). 
 
4.4. Extraction, isolation and characterization of the constituents of Haliclona cymaeformis 
The sample of Haliclona cymaeformis (7.6 kg net weight) was thawed, homogenized with EtOH 
(10L), allowed to stand for 24 h in the dark chamber and filtered. The residue on the filter paper was 
again extracted with EtOH (2x10L), the aqueous alcoholic extracts were combined, evaporated at 
reduced pressure to give ca. 700 ml and extracted with EtOAc (3x1L). The EtOAc extracts were 
combined and concentrated at reduced pressure to give a crude EtOAc extract (21g). This extract was 
applied to flash chromatography column of Si Gel (150 g) and eluted with CHCl3 (frs. 1-5; 5 x 200 
mL), CHCl3-MeOH,, 49:1 (frs 6-15; 10 x 200 mL), CHCl3-MeOH,, 19:1 (frs16-20; 5x200 mL), 
CHCl3-MeOH,, 9:1 (frs 21-22; 2x500 mL), EtOAc (frs 23-24; 2 x500mL) and MeOH (frs 25-26; 2 
x500mL). Frs 18-24 were combined (3.1g), applied on the flash chromatography column of ODS-A 
gel (35g) and eluted with mixture of MeOH-H2O; 7:3 (sfr 1; 200mL), MeOH-H2O; 4:1 (sfr 2; 200mL), 
MeOH-H2O; 9:1 (sfr 3; 2x100mL), MeOH (sfr 4; 400mL), CHCl3-MeOH-H2O; 14:6:1 (sfr 5, 400mL). 
Sfr 1 (156 mg) was purified by TLC Si gel, CHCl3-MeOH-HCO2H, 19:1:0.1) to give 3.5 mg of p-
hydroxybenzaldehyde (3) and 15 mg of tetillapyrone (5 and 6). Sfr 5 (103 mg) was purified by TLC 
(Si gel, CHCl3-MeOH-HCO2H, 19:1:0.1) to give 7 mg of phenylacetic acid (4) and 17 mg of 
nortetillapyrone (7 and 8). 
Maleimide-5-oxime ( 1): yellow viscous mass; EI HRMS 122.02723 (M
+),cald for C4H4N2O2, 
122.02728.
1HNMR (300 MHz, DMSO): δ11.03 brs (-NH), 10.86 brs (=N-OH), 7.40d (J=7.6 Hz, H-4), 
5.45d (J=7.6 Hz, H-3), 
13CNMR (75.47 MHz, DMSO): δ164.37 (CO-2), 151.54 (C-5), 142.22 (CH-4), 
100.24 (CH-3). 
 
4.5. Biological Activity 
 
5.5.1. Cell Growth Assay 
 
The effect of compounds on the growth of human tumor cell lines were evaluated according to the 
procedure adopted by National Cancer Institute (NCI, USA) for the in vitro anticancer drug discovery 
screen which uses the protein-binding dye sulforhodamine B (SRB) to assess cell growth inhibition 
[13, 14] and according to the method described by Kijjoa et al. [15]. 
 
5.5.2. Antifungal Activity Determination 
Antifungal activity of maleimide-5-oxime (1), p-hydroxybenzaldehyde (3), phenylacetic acid (4), 
tetillapyrone (5 and 6) and nortetillapyrone (7 and 8) was evaluated against Candida, Aspergillus and 
dermatophyte strains: three yeasts clinical strains, one of Cryptococcus neoformans PH1, one of Mar. Drugs 2007, 5                                                  
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Candida dubliniensis PH10 and one of C. glabrata D10R, as well as, four American Type Culture 
Collection  (ATCC) type strains (C. albicans ATTC 10231, C. tropicalis ATCC 13803, C. krusei 
ATCC 6258 and C. parapsilosis ATCC 90018); one Aspergillus clinical strain (A. flavus F44), as well 
as, two ATCC type strains (A. niger ATCC 16404, and A. fumigatus ATCC 46645); five dermatophyte 
clinical strains (Microsporum canis FF1, M. gypseum FF3,  Trichophyton rubrum FF5, T. 
mentagrophytes FF7 and Epidermophyton floccosum FF9). 
The fungal isolates were identified by standard microbiology methods and stored on Sabouraud 
Dextrose broth with glycerol at -70ºC and subcultured in Sabouraud-Chloramphenicol agar. Minimal 
Inhibitory Concentration (MIC) was determined by a microdilution method according to the CLSI 
reference method M27-A2 for yeasts [16], and M38-A for filamentous fungi [17]. The test was 
performed in sterile 96 flat-bottom well microtitration plates and the medium used was MOPS-
buffered RPMI 1640. Briefly, MICs were determined for all yeasts strains with the adjusted final 
inoculum of 1-4 x 10
4 CFU/mL, prepared from a 24-48 hours culture. With filamentous fungi (except 
for Epidermophyton floccosum), the final inoculum used was 4-8 x 10
4CFU/mL, prepared from a 
sporulated culture. For Epidermophyton floccosum, the final inoculum was 8 x10
4 to 1.6 x 10
5 
CFU/mL. Two fold serial dilutions of compounds in DMSO, ranging from 250 to 15.125 μg/mL, were 
tested. Fungal growth controls, with and without DMSO, were included. The final DMSO 
concentration was 2%, and did not affect the fungal growth. In addition, reference antifungal 
compounds, fluconazole (Pfizer, United Kingdom) for yeasts and dermatophytes or amphotericin B 
(Sigma) for Aspergillus, were used as the standard antifungal drugs. Twofold serial dilutions ranging 
from 128 to 0.25 μg/mL for fluconazole and 16 to 0.063 μg/mL for amphotericin B were used. Plates 
were incubated at 30ºC for 48 hours for Candida species, 72 hours for Cryptococcus neoformans, 4-5 
days for Aspergillus species and 8 days for dermatophytes. Quality control determinations of the MIC 
of fluconazole were ensured by testing C. parapsilosis ATCC 90018. The results were within the 
recommended limits. All determinations were performed in duplicate and three independent 
experiments lead to concordant results.  
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